ADARx Pharmaceuticals, Inc.
NASDAQ:ADRXBiotechnology
+$0.13 today
- Market cap
- $1.42B
- Beta
- 0.00
Volume 0.65M
Average 1.06M
ADRX Total Current Assets
All assets expected to be converted to cash or used up within one year.
Total Current Assets history
Currency unavailable · from the balance sheet
No Total Current Assets data reported for this period type.
Total Current Assets vs competitors
How ADRX compares with its peers on the latest reported figures
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $561.27M USD | +117.6% | +84.1% | 96.2% | |
| Mar 2026 | $366.68M USD | -2.4% | +7.8% | 82.7% | |
| Mar 2026 | $285.57M USD | — | — | 97.7% | |
| Mar 2026 | $216.88M USD | -22.2% | -15.7% | 88.4% | |
| Mar 2026 | $186.02M USD | +78.8% | +173.4% | 99.5% | |
| Mar 2026 | $137.89M USD | -15.8% | -15.1% | 46.8% | |
| Mar 2026 | $102.85M USD | -39.4% | +7.1% | 89.3% | |
| Mar 2026 | $96.2M USD | +20.4% | -15.9% | 39.3% | |
| Mar 2026 | €87.07M EUR | -41.6% | -13.5% | 87.8% | |
ADRXADARx Pharmaceuticals, Inc. | — | — | — | — | — |
| Peer median (excluding ADRX) | — | -9.1% | -3.2% | 88.4% | |
Competitors are the stored peer set for ADRX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
ADARx Pharmaceuticals, Inc.
NASDAQ:ADRX
Intrinsic Alpha fair value
Locked
Current Price
$12.82
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.